

**GlaxoSmithKline Pharmaceuticals Limited**

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

**Segment wise Revenue, Results and Capital Employed,  
under Clause 41 of the Listing Agreement**

(Rs. lakhs)

Unaudited			Unaudited		Audited
3 months ended 30.06.2006	3 months ended 30.06.2005		6 months ended 30.06.2006	6 months ended 30.06.2005	Year ended 31.12.2005
		1. Segment Revenue:			
35943	41825	a) Pharmaceuticals	74008	65399	128635
5752	5335	b) Other Businesses	11074	9803	23066
41695	47160	Total Segment Revenue	85082	75202	151701
-	-	Less: Inter Segment Revenue	-	-	-
41695	47160	Net Sales / Income from Operations	85082	75202	151701
		2. Segment Results (Profit before Interest and Tax):			
12468	15606	a) Pharmaceuticals	26649	22760	41630
1100	930	b) Other Businesses	2050	1453	5199
13568	16536	Total Segment Results	28699	24213	46829
		Add/(Less):			
705	512	(i) Interest Income (net)	1493	1060	2345
(314)	(302)	(ii) Unallocable Income Net of Unallocable Expenditure	(276)	(432)	(1383)
13959	16746	Total Profit Before Tax and Exceptional Items	29916	24841	47791
		3. Capital Employed (Segment Assets less Segment Liabilities):			
17184	17379	a) Pharmaceuticals	17184	17379	11975
7758	7851	b) Other Businesses	7758	7851	7563
24942	25230	Total Capital Employed in Segments	24942	25230	19538

Notes:

- 1 Refer notes 4 and 6 of the aforesaid unaudited financial results for the half year ended 30th June, 2006.
- 2 (i) The Company is organised into two main business segments, namely:
  - Pharmaceuticals - comprising of bulk drugs and formulations
  - Others - primarily comprising of veterinary formulations, feed supplements, fine chemicals, diagnostics, laboratory equipment and exports mainly relating to pharmaceuticals.

Segments have been identified and reported taking into account, the nature of products and services, the differing risks and returns, the organisation structure, and the internal financial reporting systems.

(ii) Segment Revenue in each of the above domestic business segments primarily includes sales (net of excise duty), processing charges, consignment sales commission, clinical research and data management and export incentives in the respective segments.

(iii) Segment Revenue, Results, Assets and Liabilities include the respective amounts identifiable to each of the segments and amounts allocated on a reasonable basis.